Menu
Back to Journals » Clinical and Experimental Gastroenterology » Volume 5
Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review
Received 11 October 2011
Accepted for publication 8 December 2011
Published 12 January 2012 Volume 2012:5 Pages 1—10
DOI https://doi.org/10.2147/CEG.S23274
Review by Single anonymous peer review
Peer reviewer comments 4
Allen W Mangel1, Gareth A Hicks2
1RTI Health Solutions, Research Triangle Park, NC, 2Tioga Pharmaceuticals Inc, San Diego, CA, USA
Abstract: Irritable bowel syndrome (IBS) is a multifactorial condition with principal symptoms of pain and altered bowel function. The kappa-opioid agonist asimadoline is being evaluated in Phase III as a potential treatment for IBS. Asimadoline, to date, has shown a good safety profile and the target Phase III population – diarrhea-predominant IBS patients with at least moderate pain – was iteratively determined in a prospective manner from a Phase II dose-ranging study. The clinical data in support of this population are reviewed in this article. Furthermore, the scientific rationale for the use of asimadoline in the treatment of IBS is reviewed. Considering the high patient and societal burdens of IBS, new treatments for IBS represent therapeutic advances.
Keywords: irritable bowel syndrome, kappa-opioid agonist, asimadoline, visceral pain, visceral hypersensitivity
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.